Congratulations to Kangtai Bio for its IPO

Our customer, Shenzhen Kangtai Biological Products Co., Ltd., was successfully IPO in 2017. Congratulations.

The main products of Kangtai Biological are recombinant hepatitis B vaccine (Saccharomyces cerevisiae) (10μg, 20μg, 60μg three specifications), Haemophilus influenzae type b (Haemophilus influenzae type b), Haemophilus influenzae type b Combined vaccine, measles rubella combined attenuated live vaccine, cell-free disinfecting Haemophilus influenzae type b joint vaccine and other products.

Kangtai Biological is one of the earliest companies engaged in the production of recombinant hepatitis B vaccine (Saccharomyces cerevisiae). Currently, the two production bases are located in Nanshan District, Shenzhen Science and Technology Industrial Park and Daxing District, Beijing Zhongguancun Science Park Daxing biomedical industry base. There are an area of ​​62,400 square meters of Kangtai bright light of the vaccine production base is under construction, production scale ranks the forefront of the industry. The company has domestic advanced vaccine research and development centers, through years of continuous research and innovation, has now formed a rich product line, product structure and good market prospects with the vaccine product echelon.

Congratulations to Kangtai Biological again.  Sincerely hope our cooperation with the Kangtai biological into a higher level.